Kursvinnare Hälsovård 2013-2018 (slutdatum 181130)
1 år
| Bolag | Totalavk. |
| Oasmia Pharma | 344% |
| Rhovac | 245% |
| DexTech Medical | 229% |
| BioArctic | 226% |
| Cantargia | 146% |
| Oncopeptides | 137% |
| Double Bond Pharma | 137% |
| Sedana Medical | 126% |
| IRLAB Therapeutics | 122% |
| MedCap | 104% |
3 år
| Bolag | Totalavk. |
| Hansa Biopharma | 888% |
| Spectracure | 513% |
| Biotage | 432% |
| Stille | 354% |
| Genovis | 279% |
| CellaVision | 258% |
| DexTech Medical | 258% |
| SyntheticMR | 236% |
| Bactiguard Holding | 219% |
| MedCap | 206% |
5 år
| Bolag | Totalavk. |
| Hansa Biopharma | 3317% |
| CellaVision | 1420% |
| Biotage | 1108% |
| Stille | 824% |
| Probi | 765% |
| Vitrolife | 753% |
| SyntheticMR | 524% |
| Boule Diagnostics | 491% |
| Xvivo Perfusion | 353% |
| RLS Global | 313% |
Klicka på respektive länk ovan för analys av perioden då bolaget blev en kursvinnare